ZyVersa Therapeutics, Inc. (ZVSA)

ZyVersa Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-24.49	-24.95	-9.41	-98.3	-14.12	-8.08
Depreciation & Amortization	-	-	0.01	0.01	0.01	0.01
Other Amortization	0.06	0.06	-	-	0.04	0.32
Asset Writedown & Restructuring Costs	18.65	18.65	-	93.33	-	-
Stock-Based Compensation	0.12	0.22	0.71	1.19	3.58	4.14
Other Operating Activities	-0.26	-0.61	0.21	-7.56	-0.05	-0.44
Change in Accounts Payable	0.61	0.69	0.89	2.41	4.54	-0.31
Change in Other Net Operating Assets	1.16	0.83	0.08	0.19	1.12	-0.71
Operating Cash Flow	-4.14	-5.11	-7.52	-8.72	-4.89	-5.08
Long-Term Debt Issued	-	-	-	-	-	5.23
Net Debt Issued (Repaid)	1	-	-	-	-	5.23
Issuance of Common Stock	2.05	2.05	6.54	19.08	-	-
Repurchase of Common Stock	-	-	-	-0.01	-	-
Other Financing Activities	-0.22	1.63	-0.63	-2.42	-0.1	-
Financing Cash Flow	2.83	3.69	5.91	5.96	1.87	5.23
Net Cash Flow	-1.31	-1.43	-1.61	-2.76	-3.02	0.15
Levered Free Cash Flow	-2.08	-2.88	-4.09	-5.46	-1.65	-2.02
Unlevered Free Cash Flow	-1.75	-2.56	-3.92	-5.46	-1.43	-1.83
Change in Working Capital	1.77	1.52	0.97	2.6	5.66	-1.02

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 4, 2026

Data Sources Report a data error